H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $200 from $190 and keeps a Buy rating on the shares following the Q4 report. The company reported “impressive” performance with its marketed product portfolio, “setting the stage for significant long-term growth,” the analyst tells investors in a research note. The firm sees multiple near- and medium-term clinical and regulatory catalysts for Axsome shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $200 from $190 at Truist
- Axsome Therapeutics price target raised to $192 from $143 at RBC Capital
- Axsome Therapeutics price target raised to $153 from $133 at Needham
- Positive Outlook for Axsome Therapeutics Amid Key Developments and Growth Potential
- Promising Growth and Market Expansion Drive Buy Rating for Axsome Therapeutics